In our present study, we aimed to evaluate the relationship of PIK3CA mutations and GSs representing PI3K pathway activation with key biological features of BC and short-term aromatase inhibitor–induced suppression of Ki67, a validated intermediate endpoint for benefit from endocrine therapy [11,36]. This evidence concerns the gene CYP19A1 and breast cancer.